<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: We report a prospective multicenter phase II study of haploidentical hematopoietic stem cell transplantation using CD3/CD19-depleted grafts after reduced intensity conditioning with fludarabine, thiotepa, melphalan and OKT-3 </plain></SENT>
<SENT sid="1" pm="."><plain>DESIGN AND METHODS: Sixty-one adults with a median age of 46 years (range 19-65 years) have been enrolled </plain></SENT>
<SENT sid="2" pm="."><plain>Diagnoses were <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n=38), <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n=8), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n=6), <z:mp ids='MP_0009440'>myeloma</z:mp> (n=4), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n=3), <z:hpo ids='HP_0005550'>chronic lymphatic leukemia</z:hpo> (n=1) and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n=1) </plain></SENT>
<SENT sid="3" pm="."><plain>Patients were considered high risk because of refractory disease (n=18), cytogenetics (n=6), complete remission (≥ 2) (n=9), chemosensitive relapse in partial remission (n=4) or relapse after prior hematopoietic stem cell transplantation (n=15 allogeneic, n=8 autologous, n=1 both) </plain></SENT>
<SENT sid="4" pm="."><plain>At haploidentical hematopoietic stem cell transplantation, 30 patients were in complete remission and 31 in partial remission </plain></SENT>
<SENT sid="5" pm="."><plain>Grafts contained a median of 7.0 × 10(6) (range 3.2-22) CD34(+) cells/kg, 4.2 × 10(4) (range 0.6-44) CD3(+) T cells/kg and 2.7 × 10(7) (range 0.00-37.3) CD56(+) cells/kg </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Engraftment was rapid with a median of 12 days to granulocytes more than 0.5 × 10(9)/L (range 9-50 days) and 11 days to platelets more than 20 × 10(9) (range 7-38 days) </plain></SENT>
<SENT sid="7" pm="."><plain>Incidence of grade IIIV <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host-disease</z:e> and <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host-disease</z:e> was 46% and 18%, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Non-relapse mortality on Day 100 was 23% and 42% at two years </plain></SENT>
<SENT sid="9" pm="."><plain>Cumulative incidence of relapse/progression at two years was 31% </plain></SENT>
<SENT sid="10" pm="."><plain>Kaplan-Meier estimated 1-year and 2-year overall survival with median follow up of 869 days (range 181-1932) is 41% and 28%, respectively </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: This regimen allows successful haploidentical hematopoietic stem cell transplantation with reduced intensity conditioning in high-risk patients lacking a suitable donor </plain></SENT>
<SENT sid="12" pm="."><plain>(clinicaltrials.gov identifier:NCT00202917) </plain></SENT>
</text></document>